LONDON, ON (October 2019) – KGK Science Inc. (“KGK”) is a different company than it was in 2018. Following their acquisition by Auxly Cannabis Group Inc. (TSX.V: XLY) (OTCQX: CBWTF) (“Auxly”), KGK has seen significant growth as a leading contract research organization in the nutraceutical and cannabinoid industries. A testament to this growth is the addition of Dr. Corey Hilmas as its Chief Regulatory Officer, bringing substantial experience and industry credentials to KGK, allowing them to expand and bolster their regulatory services.
Auxly completed its acquisition of KGK in August 2018 as part of a strategy to leverage their scientific and clinical research abilities. In addition to Auxly’s acquisition of Dosecann, KGK as a subsidiary adds bench strength, specifically to further their cannabinoid-based product development efforts. In July 2019, it was announced that Imperial Brands PLC will invest approximately $123 million in Auxly, granting them global licenses to Imperials Brands’ vaping technology and accelerating their plans to focus on the development of science-backed, innovative, branded derivative products (Auxly Cannabis Group Inc.)
“KGK is thrilled with the opportunity to partner and grow with Auxly,” commented Najla Guthrie, President and CEO of KGK Science. “Our partnership continues a trajectory of growth in cannabis research and most importantly enhances our expertise to offer best-in-class research services to the nutraceutical industry.”
In alignment with this growth trajectory is the addition of Dr. Corey Hilmas to KGK as Chief Regulatory Officer. Dr. Hilmas, a medical doctor with a degree from the University of Maryland School of Medicine and a doctorate in CNS neurotoxicology and pharmacology, brings extensive U.S. FDA experience after having served as an NDI notification toxicology reviewer and as a branch chief within the Division of Dietary Supplement Programs at the FDA under Dr. Daniel Fabricant. In addition to working on enforcement matters related to labeling, and claims, he also served as an expert witness for the FDA, resulting in an FDA Award of Merit.
Most recently, Dr. Hilmas was the Vice President of Scientific and Regulatory Affairs at the Natural Products Association where he oversaw the development and implementation of scientific, regulatory, educational, and compliance programs (cGMP, Natural Seal, TruLabel, etc.).
“The nutraceutical and cannabinoid industries are always changing to drive innovation,” says Hilmas. “With that innovation comes the need to seek regulatory solutions for marketing opportunities and reducing regulatory risk. I look forward to providing leadership, experience, and customer service on behalf of KGK to its growing clientele.”
Contact: Lauren Redman, Director of Marketing | (519) 438-9374 x 254 | lredman@kgkscience.com
About KGK Science Inc.
As a global Contract Research Organization (CRO), KGK Science performs a productive and pioneering role in the realm of scientific study. For over two decades, it has offered well-designed, customized solutions to each of its clients, consolidating its scientific, clinical, commercial, and regulatory abilities into one full-service package. Equipped with state-of-the-art technologies, novel research techniques, and a seasoned team of thought leaders, KGK Science remains at the forefront of its industry. By seamlessly matching its experience with its drive for innovation, this CRO can respond effectively to expanding trade and consumer demands.